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Calcium antagonists in exercise-induced
asthma
SIR,-The report by Dr K R Patel (21 March,
p 932) that the calcium antagonist verapamil
inhibits exercise-induced asthma is supported
by the observations of Cerrina and co-workers,'
who report that nifedipine, another antagonist
of calcium influx, also prevents the broncho-
constrictor response to exercise in asthmatics.
In discussing the mechanism of exercise-
induced asthma both Dr Patel and Cerrina
et al suggest that the release of spasmogens
from lung mast cells may play a role in this
condition and that calcium antagonists, in
addition to relaxing smooth muscle, may
prevent exercise-induced bronchospasm by
inhibiting the calcium-dependent release of
these spasmogens.
In recent studies on the antigen-induced
release of spasmogens from sensitised frag-
ments of human lung, using well-established
techniques,2 we have confirmed that there is
an absolute requirement for extracellular
calcium ions in the release processes. However,
nifedipine and verapamil at concentrations up
to 100 Ftmol/l failed to inhibit the release of
histamine from human lung when the drug
was preincubated with the tissue for 30
minutes before challenge. We did observe,
however, that verapamil at 100 ,umol/l, but
not at 10 ,umol/l, inhibited the release of slow-
reacting substance. In addition, verapamil
(500 pmol/1-150 ,umol/l) inhibited the spasmo-
genic effect of histamine (1 jig/ml) on human
superfused bronchial smooth muscle with a
concentration effective in 50% of cases
(EC50) of 9 [imol/l.
Spasmogens derived from mast cells are
unlikely to make a major contribution to the
bronchoconstrictor response to exercise in
asthmatics.3 Even if their contribution is
greater than currently believed the results
presented here suggest that calcium antagonists
exert their inhibitory effects in exercise-
induced asthma on the constrictor responses
of bronchial smooth muscle rather than on
the release of spasmogens from mast cells.
Nifedipine was a gift from Bayer UK Limited and
verapamil was a gift from Abbott Laboratories
Limited.
P R BUTCHERS
I F SKIDMORE
C J VARDEY
A WHEELDON
Department of Biochemistry,
Glaxo Group Research Limited,
Ware, Herts SG12 ODJ
Cerrina J, Denjean A, Alexandre G, Lockhart A,
Duroux P. Amn Rev Resp Dis 1981;123:156-60.2 Butchers PR, Fullarton JR, Skidmore IF. Thompson
LE, Vardey CJ, Wheeldon A. Br J Pharmacol
1979 ;67 :23-32.
3Deal EC, Wasserman SI, Soter NA, Ingram RH,
McFadden ER. J Clin Invest 1980;65:659-65.
Are fibre supplements really necessary
in diverticular disease of the colon?
SIR,-What should we do when clinical
impressions over a number of years are not
confirmed by a randomised, cross-over, double-
blind controlled trial? With only an occasional
exception patients with symptomatic uncom-
plicated diverticular disease of the colon report
a persisting improvement when they take extra
dietary fibre, often without an additional
bulking agent. Personally I accept the verdict
of my patients and then look doubly carefully
at the double-blind trial.
The trial which you report by Mr M H
Ornstein and others (25 April, p 1353) surely
has an obvious fallacy. I was taught that the
dose of a drug is that which has the desired
effect without causing side effects, and the same
is true for dietary supplements. To give a
standard amount, and a small one at that, to
every patient irrespective of their real need
invites statistical disaster. In their subsequent
letter (16 May, p 1629) the authors admit that
"it is important to give sufficient bran or
ispaghula to relieve straining and the amount
will vary greatly between patients." This is
equally true for other symptoms. With their
own words they themselves condemn their
own trial, which I believe is meaningless and
dangerously misleading, although it appears to
be beautifully designed and executed.
I am not alone in thinking that this paper
should have been published in a specialist and
not a leading world medical journal. This is not
the first time that a clinical trial has given a
dubious answer and I greatly welcome the
article in your new series "Statistics in
Question" about assessing clinical trials (16
May, p 1605).
F AVERY JONES
London W2 6DA
SIR,-It is regrettable that Mr M H Ornstein
and others (25 April, p 1353), after carrying
out an extensive clinical trial, have sub-
sequently appeared to misinterpret their
results. They have demonstrated that in-
creasing the fibre intake of their patients with
diverticular disease by 4 6 g was inadequate to
produce sufficient relief of symptoms to reach
levels of statistical significance, although the
lowest mean symptom scores for pain,
bowel symptoms, and general symptoms were
seen when patients were taking bran. An
increase of mean stool weight of less than 20 g
daily and an increase in stool frequency from
9 55 to 10-34 per week may be inadequate to
produce the desired effect on colonic behaviour.
I have found in clinical practice that sympto-
matic relief in diverticular disease is best
achieved by increasing fibre intake by 20 g.
This more than doubles the total fibre intake
of most patients and almost invariably has a
marked effect on bowel habit. Although
patients will tolerate only a limited amount of
bran, as Mr Ornstein and others state (16
May, p 1629), they will tolerate a much
greater increase in fibre intake in the form of
wholemeal bread, high-fibre breakfast cereals,
etc.
A direct comparison has been made between
this trial and a similar trial in Oxford.' The
differences in results are difficult to explain,
but could have been due to differences in the
patients selected for the trials. Those at Oxford
were all suffering from severe symptoms and all
had abdominal pain in addition to bowel
symptoms. The initial fibre intake of the
patients may have been different. Differences
in scoring techniques may have been impor-
tant in the assessment of true differences in
scores. In the previous trial a cross-over design
was deliberately not used. The effect of alter-
ing fibre intake on bowel behaviour may per-
sist for some months, in which case cross-over
studies are inappropriate.
In the Oxford trial patients took the crisp-
bread instead of bread, so that the placebo
group had no increase in their normal fibre
intake. In the present trial the control group
did, in fact, have an increased fibre intake,
according to Mr Ornstein and his colleagues
(p 1629), and it could be argued that there was
no valid control group-only three different
treatment groups.
The main value of this study has been to
emphasise that small differences in fibre intake
(equivalent to a small 50-g (13-oz) packet of
peanuts daily) may not be effective in treating
diverticular disease. The recommended intake
of many proprietary "bran" preparations is
totally inadequate. Many gastroenterological
and surgical clinics have found that a high-
fibre diet (that is, 40 g a day-not 22 g as in
this study) is effective in treating diverticular
disease, but the optimal increase in dietary
fibre required remains to be established scien-
tifically.
JOHN BRODRIBB
Plymouth General Hospital,
Plymouth PL1 4AT
I Brodribb AJM. Lancet 1977;i:664-6.
SIR,-Despite the spirited criticism of Dr J R
Thornton, Mr R T Burkitt, and Dr K 0 A
Vickery (9 May, p 1546), it was unrealistic to
have expected Mr M H Ornstein and his
colleagues to retract the conclusions of their
paper (25 April, p 1353)-namely, that dietary
fibre supplements "do no more than relieve
constipation" and "are unnecessary in the
long-term management of uncomplicated
diverticular disease." As it stands, however,
their paper will undoubtedly be misquoted as
its finer points become clouded by the passage
of time. It is simply not enough for the authors
to suggest subsequently (16 May, p 1629) that
they made no claims concerning prevention of
the disease; the fact that they neither men-
tioned this in their paper nor pointed out the
total lack of other trial data relating to prophy-
laxis represents an important omission from
their original and otherwise useful contribution.
Mr Ornstein and his colleagues are quite
right in saying that a trial to test the lifelong
prophylactic effect of fibre is impossible; a
more realistic yet equally important question
and, incidentally, one which they are in a
prime position to tackle is: "Do fibre supple-
ments, when given long term to patients with
uncomplicated diverticular disease, prevent
progression to the more serious stages of this
common condition ?" If the trial is explained,
patients' co-operation should be no more of a
problem in a trial to answer this question than,
say, in a trial of antihypertensive therapy in the
prevention of myocardial infarction or stroke.
It is a shame that the Index Medicus does not
link original papers with the correspondence
that they generate, for this might help to
rectify sweeping overstatement by authors and
prevent uncritical overinterpretation by
readers. This paper and the constructive
ensuing debate are a fair example of this
problem.
JOHN NORTHOVER
Central Middlesex Hospital,
London NWIO 7NS
Multiple sclerosis
SIR,-Your leading article on multiple sclerosis
(14 February, p 502) suggests that in a cross-
sectional survey the median duration of the
disease can be calculated by doubling the time
from onset to prevalence day. The fallacy of
this statement can be demonstrated with an
extreme but simple example.
Suppose that 80% of patients with a
particular disease survive for six months after
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onset, while the remaining 20% survive for six
years. Then a cross-sectional study can be
expected to contain 250/ short-term survivors
and 75%, long-term survivors, because of the
greater risk of short-term survivors being dead
before "prevalence day." Thus, assuming a
stable population and incidence, we can expect
a median interval from onset to prevalence day
of two years. The recommended method would
therefore estimate the median survival to be
four years compared to the true figure of six
months.
It is also apparent from this example that
an increase in estimated median survival can
result from a shortening of life expectancy
among those with a poor prognosis.
R J PRESCOTT
Medical Computing and Statistics Unit,
Medical School,
Edinburgh EH8 9AG
***Poskanzer et all point out (p 236) the
statistical problem: "Assuming that there is
no change in the pattern of a disease, average
duration could be estimated as twice the
period from onset to prevalence day. It is
therefore assumed that the duration among a
group of patients identified on prevalence day
will approximate to a normal distribution and
that ascertainment of nearly all existing cases
will be achieved, especially those cases with a
recent onset of the disease. The latter require-
ment has probably not been fully met in each
of the four surveys in the Orkneys and
Shetlands. However, the method can be
applied by using information discovered later
about cases with onset close to prevalence day.
The effect of not identifying all cases with
recent onset overestimates the average duration.
If it is assumed, however, that the error
resulting from the exclusion of recent-onset
cases is relatively constant over the four
surveys, the data can be used to determine if
the duration has changed over time but not to
determine the actual duration of the disease."
Space did not allow us to go into these details
about the statistical method in our leading
article, but we are grateful to Dr Prescott for
writing.-ED, BM7.
'Poskanzer DC, Prenney LB, Sheridan JL, Yon Kondy
J. J Epidemiol Community Health 1980;34:229-39.
Trial of folate treatment to prevent
recurrence of neural tube defects
SIR,-We have been extremely interested to
read the recent papers by Dr K M Laurence
and others (13 December, p 1592; 9 May,
p 1509) on the relationship of maternal diet
and folic acid supplementation to neural tube
defect recurrence. Their observations on red
cell folate levels support our earlier work,' and
their conclusions regarding folate supplement
point in the same direction as the results of our
supplementation study,' full details of which
will be published shortly.3 We note that the
Cardiff group had methodological problems,
as we did. We are puzzled by their use of the
term "double-blind" in their more recent
paper, which can only have applied until six
to nine weeks of gestation, when blood folate
levels were estimated and "non-compliers"
were identified. The high rate of non-com-
pliance must also have disappointed the
authors. We entirely endorse their view that
further studies are needed, directed towards
the following ends:
(1) To provide further confirmation that
vitamin prophylaxis is effective. Our own con-
tinuing studies remain encouraging, but among
the defects in the offspring of fully "supple-
mented" women in our second cohort are one
recurrence of frank neural tube defect (south-
east England); one small, skin-covered lesion
without neurological deficit (Northern Ireland);
and one very large third fontanelle without
involvement of brain or meninges (Yorkshire).
(2) To define further the role of folic acid
and other vitamins. We regret that Dr
Laurence and his colleagues chose to describe
Pregnavite Forte F, a vitamin and iron
preparation containing folic acid, as "an
expensive blunderbuss preparation." We
chose it because our earlier studies' demon-
strated low first-trimester blood levels of
ascorbic acid and riboflavin as well as folic
acid in mothers bearing fetuses with central
nervous system defects. It is certainly more
expensive than folic acid, but should it prove
to be more effective the cost (less than 5p
daily) would be bearable.
(3) To study carefully mothers who are
enrolled for supplementation but who comply
only in part. The South Wales "non-compliers"
may have complied in part, and details of the
two who had recurrences are crucial. It is only
from this group that we can discover the
minimum effective period of supplementation.
There is considerable urgency. The medical
correspondent of The Times has advocated (8
May) vitamin supplementation on the basis of
our series and those of the Cardiff group. It
can no longer be assumed that mothers not
given vitamin supplements by research
workers necessarily have none. There is also a
danger of "do-it-yourself" supplementation
by mothers obtaining over-the-counter vitamin
preparations, none of which contains folic acid.
R W SMITHELLs
SHEILA SHEPPARD
C J SCHORAH
University Department of
Paediatrics and Child Health,
Leeds LS1 3ET
N C NEVIN
Department of Medical Genetics,
Queen's University,
Belfast
MARY J SELLER
Paediatric Research Unit,
Prince Philip Research Laboratories,
Guy's Hospital Medical School,
London SE1 9RT
Smithells RW, Sheppard S, Schorah CJ. Arch Dis
Child 1976;51:944-50.
2Smithells RW, Sheppard S, Schorah CJ, et al. Lancet
1980;i :339-40.
3Smithells RW, Sheppard S, Schorah CJ, et al. Arch
Dis Child (in press).
SIR,-We read with interest the article by
Professor K M Laurence and his colleagues
(9 May, p 1509) on folate treatment before
conception to prevent recurrence of neural-
tube defects.
For many years our research group in the
University of Aston has been interested in the
metabolism of folic acid in mammals, including
man. Our results in man' show that, in patients
receiving a dose of 5 mg of folic acid, the
dominant urinary species is unmetabolised
folic acid up to 24 hours after the dose.
Experiments with mammalian dihydrofolate
reductase have shown that folic acid is only a
very poor substrate of this enzyme and
inhibits the reduction of dihydrofolate with a
KI of 1 [Lmol/l (A Sahota, personal com-
munication). These results suggest that any
folic acid absorbed unchanged from the gut
persists unchanged in man for some con-
siderable time. Folic acid itself does not occur
naturally, the naturally occurring folates being
derivatives of tetrahydrofolic acid. We there-
fore feel that it is time that the practice of
giving folic acid, particularly in large doses,
is reviewed. A dose of 4 mg of folic acid
would have some inhibitory effect on dihydro-
folate reductase.
Additionally, folic acid has been shown to
inhibit dihydropteridine reductase2 a key
enzyme in neurotransmitter biosynthesis. This
enzyme is missing in some forms of atypical
phenylketonuria,3 with very serious results.
The action of folic acid on the developing
fetus could therefore be similar to that of
aminopterin, a potent inhibitor of dihydrofolate
reductase and dihydropteridine reductase, and
preparations which contain trimethoprim,
which also inhibits these reductases.'
We would like to suggest that it would be
prudent to avoid any problems that may be
caused by folic acid by using a reduced folate
such as calcium leucovorin.
PATRICIA A BARFORD
ANNE E PHEASANT
Department of Cheniistry,
University of Aston,
Birmingham B4 7ET
Saleh AM, Pheasant AE, Blair JA, Allan RN. Biochem
Soc Trans 1980;8:566-7.
'Brown SE. PhD thesis, University of Aston, 1981.
3 Kaufman S, Holtzman NA, Milstein S, Butler IJ,
Krumholz A. N Engi J Med 1975;293:785-90.
Masked advertising?
SIR,-DrN Davis (9 May, p 1548) is concerned
about drug company sponsorship of a continu-
ing education programme, organised by the
Centre for Medical Education at the University
of Dundee, where the company's products are
mentioned. I would make the following points
in reply.
(1) I believe that the pharmaceutical industry
does have a role in education of practitioners
in the subject areas in which the companies
have an interest. Just as clinical trials are done
in conjunction with university departments, so
also should there be collaboration in the
production of educational materials. This is
reasonable provided that there is editorial
independence. This was the case in this series.
The content was based on patients seen in a
busy general practice and vetted by a hospital
specialist experienced in each of the areas
discussed. Reference to drugs was not limited
to one company's products.
(2) Therapeutics is an area in which general
practitioners express a demand for continuing
education. Ifprogrammes are to be meaningful
and related to day-to-day practice of a general
practitioner it is not possible to avoid reference
to individual drugs. It is our experience that
many general practitioners prefer reference to
be made to the trade rather than to the generic
names.
(3) Our interest at the Centre for Medical
Education is in exploring methods of continu-
ing education in medicine. We have identified
some characteristics of programmes which are
likely to ensure their success and these are
incorporated in the series. The approach seems
to be appreciated by many doctors. Of the first
100 doctors replying to a questionnaire we have
sent out, 98 expressed a desire to receive a
further series and some offered to pay for this.
We are at present completing a report
evaluating the project in detail.
